NK-104 is a novel potent inhibitor of the rate-limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, and has been shown to be a highly effective agent in lowering blood cholesterol. In the present study, NK-104 was orally administered to Wistar rats at a dose of 0.3, 1, 3 or 010 mg/kg for 6 months for examination of toxicity. Additional recovery groups of 8 rats each of both sexes receiving 0 and 10 mg/kg were maintained without treatment for 1 month in order to assess recovery. As a result, no toxicological changes were observed in general signs, body weight, food intake, ophthalmological examination, urinalysis, hematological and blood chemical examinations for organ weights. An autopsy revealed thickening of the forestomach mucosa in both sexes at a dose of 1 mg/kg or more. This change was microscopically recognized as hyperkeratosis and hypertrophy of the spinous layer associated with both cell infiltration of the mucosal propria and edema of sub-mucosa in the forestomach in both sexes at doses of 3 and 10 mg/kg. Forestomach changes were not observed in any cases after 1 month cessation of drug treatment. The non-toxic dose of NK-104 in the 6-month repeated oral toxicity study in rats is estimated to be 1 mg/kg/day.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2131/jts.23.supplementv_713 | DOI Listing |
J Oral Rehabil
January 2025
Department of Masticatory Function and Health Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (Former Name: Tokyo Medical and Dental University), Tokyo, Japan.
Background: Awake bruxism involves masticatory muscle activity during wakefulness, potentially leading to clinical concerns. Accurate electromyography (EMG) assessment is challenging with brief durations.
Objective: To establish a reliable, short-term measure for nonfunctional masseter muscle activity during wakefulness.
Sleep Breath
January 2025
Department of Oral Medicine, Sedation and Imaging, Hadassah Medical Center, Faculty of Dental Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Background: The repeated airway obstructions in the common disorder Obstructive Sleep Apnea (OSA) cause health risks. Continuous Positive Airway Pressure (CPAP), the standard treatment, faces adherence challenges. Mandibular Advancement Devices (MADs) have been used successfully for mild to moderate OSA, as a good alternative for these patients.
View Article and Find Full Text PDFJ Stomatol Oral Maxillofac Surg
January 2025
Department of Oral and Maxillofacial Surgery, Vishnu Dental College, Bhimavaram, India. Electronic address:
Introduction: Alveolar cleft grafting is crucial in cleft lip and palate rehabilitation, promoting maxillary continuity and facilitating dental development. While autologous bone grafts are the gold standard, combining them with platelet-rich plasma (PRP) and xenografts like Bio-Oss has the potential to enhance bone regeneration and long-term stability. This study aimed to evaluate the synergistic effects of combining autologous cortico-cancellous bone grafts, PRP, and Bio-Oss in alveolar cleft repair.
View Article and Find Full Text PDFJMIR Res Protoc
January 2025
Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada.
Background: Telehomecare monitoring (TM) in patients with cancer is a complex intervention. Research shows variations in the benefits and challenges TM brings to equitable access to care, the therapeutic relationship, self-management, and practice transformation. Further investigation into these variations factors will improve implementation processes and produce effective outcomes.
View Article and Find Full Text PDFVaccine
January 2025
Indian Council of Agricultural Research (ICAR)-Indian Veterinary Research Institute (IVRI), Hebbal, Bengaluru 560024, India. Electronic address:
As pregnancy can adversely affect the immune response of vaccination against foot and mouth disease virus (FMDV) due to physiological immunosuppressive milieu, we tested the effect of FMDV vaccination during mid-gestation on the antibody response. Pregnant and non-pregnant cows of crossbred and indigenous breed (n = 28/group) were vaccinated with inactivated FMD vaccine covering O, A, and Asia1 serotypes and the sera were harvested at weekly interval till day 42 post-vaccination. Virus neutralization test (VNT) was done and the analysis of log VN antibody titer by mixed model ANOVA indicated that pregnancy did not significantly affect the log VN titer for FMDV serotype O and Asia1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!